Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Merck
US Army
QuintilesIMS
AstraZeneca

Generated: July 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,402,874

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,402,874 protect, and when does it expire?

Patent 9,402,874 protects COPAXONE and is included in one NDA.

This patent has eighty-one patent family members in thirty-two countries.

Summary for Patent: 9,402,874
Title:Low frequency glatiramer acetate therapy
Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Inventor(s): Klinger; Ety (Tel Aviv, IL)
Assignee: YEDA RESEARCH & DEVELOPMENT CO., LTD. (Rehovot, IL)
Application Number:14/673,257
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,402,874
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,402,874
Patent Claim Types:
see list of patent claims
Use; Delivery; Formulation;

Drugs Protected by US Patent 9,402,874

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING MS BY ADMINISTERING COPAXONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,402,874

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077896 ➤ Sign Up
Argentina 099078 ➤ Sign Up
Austria 15421 ➤ Sign Up
Australia 2010284666 ➤ Sign Up
Canada 2760802 ➤ Sign Up
Canada 2876966 ➤ Sign Up
China 102625657 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
AstraZeneca
Argus Health
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.